# RLS Radiopharmacies

Type: Company

Source: Healthcare Intelligence Brief — https://gethealthbrief.com/entity/rls-radiopharmacies
Canonical HTML page: https://gethealthbrief.com/entity/rls-radiopharmacies

## Timeline

- **2026-08-20**: H1 2026 results announced — Telix released its half-year results, reporting US$68 million invested in therapeutics R&D and highlighting late-stage program ProstACT Global.
- **2026-08-20**: ATM facility established — Telix entered into an equity distribution agreement with Morgan Stanley & Co. LLC and William Blair & Company, L.L.C. to establish an at-the-market equity facility for ADS issuance at prevailing market prices.
- **2026-06-30**: H1 2026 reporting period ended — Telix's half-year financial reporting period closed for the six months ended June 30, 2026.

## Recent coverage (1 stories)

### Telix H1 2026: $68M R&D Fuels Precision Medicine Manufacturing Push
2026-08-20 18:11:37 · Sentiment: Positive · Impact: 6/10 · Sources: 2

For healthcare and health IT leaders, Telix's half-year update is a supply-chain signal: the company is expanding radiopharmaceutical manufacturing across four countries to support precision medicine demand. The US$68 million therapeutics R&D investment and TMS expansion point to more reliable access to short-lived isotopes.
Full story: https://gethealthbrief.com/story/telix-h1-2026-precision-medicine-manufacturing

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://gethealthbrief.com/guides/methodology for the full editorial methodology.